PharVision Advisers’s Uber UBER Stock Holding History

PharVision Advisers’s Portfolio UBER Stock Details UBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,060	Closed	-$250K	–	616
2025 Q4	$250K	Buy	+3,060	New	+$276K	0.13%	388
2025 Q2	–	Sell	-4,461	Closed	-$325K	–	433
2025 Q1	$325K	Buy	4,461 +758	+20%	+$54.6K	0.45%	81
2024 Q4	$223K	Buy	+3,703	New	+$264K	0.19%	260

Other funds holding UBER

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIF

Public Investment Fund Al Aqiq District, Riyadh, Saudi Arabia $12B AUM 0.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PSCM

Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PharVision Advisers's UBER Position: Q1 2026 in Review

PharVision Advisers sold out of Uber (UBER) in Q1 2026, closing a stake of 3,060 shares — an estimated $250K sold.

PharVision Advisers first reported a position in UBER in Q4 2024 and held it in 3 quarters. The position peaked at $325K in Q1 2025. 2,429 funds tracked by Wall St. Rank hold UBER as of Q1 2026.

PharVision Advisers reported no remaining Uber position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,060 Uber shares in Q1 2026, an estimated $250K.
PharVision Advisers first reported a position in Uber in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Uber position peaked at $325K in Q1 2025.
2,429 funds tracked by Wall St. Rank held Uber as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.